Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E16.38 EPS (ttm)3.72 Insider Own0.10% Shs Outstand1.63B Perf Week2.94%
Market Cap99.39B Forward P/E11.08 EPS next Y5.50 Insider Trans-13.09% Shs Float1.62B Perf Month3.55%
Income6.08B PEG1.10 EPS next Q1.19 Inst Own68.30% Short Float2.18% Perf Quarter-3.00%
Sales25.24B P/S3.94 EPS this Y185.20% Inst Trans-2.73% Short Ratio4.61 Perf Half Y1.64%
Book/sh3.96 P/B15.38 EPS next Y14.04% ROA10.10% Target Price69.75 Perf Year12.89%
Cash/sh4.87 P/C12.50 EPS next 5Y14.95% ROE117.50% 52W Range49.34 - 67.50 Perf YTD6.78%
Dividend2.56 P/FCF25.30 EPS past 5Y3.50% ROI16.90% 52W High-9.77% Beta1.60
Dividend %4.20% Quick Ratio1.60 Sales past 5Y7.90% Gross Margin77.30% 52W Low23.44% ATR1.81
Employees28000 Current Ratio1.80 Sales Q/Q8.20% Oper. Margin36.20% RSI (14)51.15 Volatility2.64% 2.73%
OptionableYes Debt/Eq5.77 EPS Q/Q30.90% Profit Margin24.10% Rel Volume1.20 Prev Close59.99
ShortableYes LT Debt/Eq5.76 EarningsOct 28 BMO Payout61.00% Avg Volume7.67M Price60.90
Recom2.50 SMA20-0.35% SMA500.25% SMA2000.28% Volume9,156,700 Change1.52%
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Dec-08-16 10:08AM  Gilead Sciences: We Can Get Past This at Barrons.com
09:19AM  3 Great Dividend Stocks with a Clearance Sale Going on Now at Motley Fool
08:00AM  Gilead's CEO Apologetic About Sovaldi's $1,000 Per Pill Price Tag at Forbes
Dec-07-16 04:17PM  AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients
08:49AM  Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
Dec-06-16 12:52PM  AbbVie, Johns Hopkins Unite for Cancer Research
10:37AM  AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH
10:30AM  Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant PR Newswire
Dec-05-16 09:15PM  New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®) PR Newswire
02:57PM  Leukemia Treatment Achieves Promising Results
10:05AM  Bond Sell-Off Could Be Huge for Stocks: 4 Analyst Top Pick Dividend Stocks to Buy Now at 24/7 Wall St.
08:55AM  AbbVie and Johns Hopkins to Collaborate on Cancer Research PR Newswire
08:50AM  AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement PR Newswire
Dec-04-16 07:30PM  Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma PR Newswire
Dec-03-16 07:00PM  IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy PR Newswire
12:03AM  [$$] New Tax Rules on Corporate Inversions Face Uncertain Future at The Wall Street Journal
Dec-02-16 11:41AM  [$$] Tax Rules on Corporate Inversions Face Uncertain Future at The Wall Street Journal
11:05AM  Uterine Fibroids Segment May Offer Opportunity for NBIX
11:04AM  AbbVies Venclexta May Become Promising Multiple Myeloma Therapy
10:04AM  Neurocrine Biosciences Pursues Womens Health Segment with Elagolix
10:04AM  Acute Myeloid Leukemia: Growth Opportuny for AbbVies Venclexta?
08:40AM  Billionaire Larry Robbins Confidently Piles Into CBS, Anthem, As Merger Battles Continue at Insider Monkey
08:04AM  Label Expansion May Boost Venclextas Growth Prospects
08:04AM  What Do Analysts Recommend for Gilead Sciences Stock?
Dec-01-16 04:55PM  FDA Orphan Drug Designation for AbbVie's Risankizumab
04:21PM  OraSure Stock Sets Up For Buy Point On Hep C Contract, Helix Win
12:12PM  Is AbbVie Inc (ABBV) A Good Stock To Buy? at Insider Monkey
11:04AM  AbbVies ABT-494 May Become Standard of Care in Immunology
10:45AM  ETFs with exposure to AbbVie, Inc. : December 1, 2016
10:21AM  AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.
10:05AM  Can AbbVies Anti-Tau Therapeutics Help Late-Stage Alzheimers Patients?
10:04AM  AbbVies Plans for ABT-555, a Novel Multiple Sclerosis Therapy
10:04AM  Major Product Developments for Pfizer
08:06AM  Why AbbVie Wants to Develop Anti-Tau Therapies
08:04AM  AbbVie Is Focused on Growth Opportunities in Neuroscience Space
Nov-30-16 05:18PM  Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar
02:00PM  AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease PR Newswire
11:20AM  Momenta's Humira Biosimilar Looks Promising (MNTA) at Investopedia
11:05AM  AbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019
10:05AM  AbbVies HCV Regimen Gets Breakthrough Therapy Designation
10:04AM  Clinical Trial Data Shows Efficacy of Elagolix to Treat Uterine Fibroids
10:04AM  Scrutinizing the HCV Market Based on Genotypes
08:32AM  Why the $324 Billion Bioeconomy Deserves a Place in Your Portfolio at Motley Fool
08:05AM  AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017
08:04AM  Phase 3 Trials Show Elagolixs Efficacy for Endometriosis Pain
07:14AM  AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : November 30, 2016
Nov-29-16 05:04PM  Next-Generation Hepatitis C Therapy May Be AbbVies Growth Driver
04:19PM  Testing of Treatment for Cystic Fibrosis Patients Begins
04:04PM  New Indications May Be Big Opportunity for AbbVies Imbruvica
02:00PM  AbbVies Financial Guidance for 2017
12:17PM  Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohns Disease Treatment at Insider Monkey
11:04AM  Elagolix May Become a Leading Uterine Fibroids Drug
10:04AM  Elagolix May Become a Strong Growth Driver for AbbVie
08:22AM  Momenta's Humira biosimilar succeeds in key psoriasis study
08:04AM  AbbVies Progress in Development and Commercialization of Venclexta
07:00AM  [$$] Big Pharma healthcare R&D steps out into the open at Financial Times
Nov-28-16 11:40AM  December 2016 Stock Considerations at Insider Monkey
11:06AM  AbbVies Imbruvica Expected to Become a Leading Oncology Drug
11:02AM  3 Top Drug Stocks for Your Retirement Portfolio at Motley Fool
10:05AM  Humira Has Been a Key Growth Driver for AbbVie in 2016
08:06AM  AbbVie Expected to Report Strong Earnings Growth in 2016
07:15AM  Short Sellers Hike Their Bets in Most Major Pharma Stocks
Nov-25-16 05:12PM  [$$] Clinical Development News, Nov. 21-25 at The Wall Street Journal
Nov-23-16 11:20AM  Smart Money Continues to Lose Confidence In McDonalds Corporation (MCD) at Insider Monkey
08:24AM  Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease
Nov-22-16 05:03PM  What Stocks to Buy as Markets Reach Record Levels
03:32PM  Enanta Pharmaceuticals Releases Results
02:04PM  Inside Eli Lillys Revenue Trends
09:55AM  AbbVie Nixes Halozyme Drug Partnership (HALO, ABBV) at Investopedia
09:40AM  Jefferies Makes Another Huge Addition to Franchise Picks Stocks Portfolio at 24/7 Wall St.
Nov-21-16 05:04PM  Copaxone May Face Competitive Pressures in the Future
03:25PM  Abbvie Ends Development Program With Halozyme
02:04PM  2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio
11:45AM  How a 15% Decline Is a Gift to Income Investors
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
07:46AM  The No. 1 Healthcare Concern Americans Want Donald Trump to Fix -- and It's Not Obamacare at Motley Fool
07:03AM  Ready to Get In on Biotech? Check Out These 3 Stocks at Motley Fool
Nov-18-16 04:42PM  J&J (JNJ) Files for Psoriasis Candidate Guselkumab in U.S.
01:43PM  Top Research Reports for Cisco, Amgen & NextEra Energy
11:04AM  Johnson & Johnson Takes Aim at AbbVie at Motley Fool
08:16AM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC at Motley Fool
06:18AM  Sanofi/Regeneron Present Sarilumab Data at ACR Meeting
Nov-17-16 06:04PM  AnacorAcquisition Added Crisaborole to Pfizers Portfolio
05:01PM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
02:23PM  10 High-Quality Stocks That Just Raised Their Dividends
10:15AM  J&J (JNJ) Stelara Gets Approval in EU for Label Expansion
Nov-16-16 12:01PM  AbbVie Treatment Found to Cure Chronic Hepatitis C Patients
08:17AM  Amgen Files for Avastin Biosimilar; Repatha Data Positive
08:12AM  Biotech Stock Roundup: Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved
Nov-15-16 05:33PM  Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib
01:10PM  7 Best Dividend Stocks to Buy for 2017 at Kiplinger
01:04PM  AbbVie's Humira a Step Closer to Approval in Europe
01:04PM  ABBVIE INC. Financials
10:47AM  J&Js Humira Rival Needs More Work (JNJ, ABBV) at Investopedia
10:04AM  Xtandi Is Expected to Witness Strong Growth Trends Going Forward
08:00AM  AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease PR Newswire
Nov-14-16 05:31PM  MSCI announces latest changes to U.S., China, emerging market indexes
05:19PM  AbbVie's (ABBV) Humira Wins CHMP Backing for Expanded Use
04:57PM  Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price
03:15PM  Merck Reports Triple-Combo Results
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM